DEA joins HHS, ONDCP for listening session with nationwide drug prescribers

DEA hosted on October 4 a listening session with HHS and Office of National Drug Control Policy officials to hear concerns from groups that represent drug prescribers nationwide as well as develop positive solutions to the issues these providers are confronted with.

DEA hosted on October 4 a listening session with HHS and Office of National Drug Control Policy officials to hear concerns from groups that represent drug prescribers nationwide as well as develop positive solutions to the issues these providers are confronted with. "DEA views the nearly 1.8 million registrants across the country as our partners and it is our duty and obligation to ensure their voices are heard," said John J. Martin, DEA Deputy Administrator who heads the Office of Diversion Control Division. "Part of DEA's regulatory and enforcement responsibilities must include productive, ongoing dialogue with these provider groups. These efforts improve our transparency, increase communication and help law enforcement understand the many challenges these providers face." Participants in the listening session include APhA, the American Medical Association, and the Federation of State Medical Boards. The meeting was part of DEA's outreach efforts to health care providers, registrants, pharmacy groups, and others who have worked with law enforcement to address key issues such as the nationwide opioid crisis.